Dr. Reju-All Debuts Pharmacist-Led Skincare Approach at AAD 2026, Engaging Nearly 5,000 Industry Professionals PR Newswire (Press Release) 13:45 Thu, 23 Apr
Video: Litifilimab for Cutaneous Lupus Erythematosus — AAD Expert Insights Dermatology Advisor 15:31 Tue, 21 Apr
AAD: Ixekizumab and Tirzepatide Boosts PsA Outcomes More Than Ixekizumab Monotherapy Dermatology Advisor 15:50 Fri, 10 Apr
AAD: Subcutaneous Amlitelimab Aids Atopic Dermatitis Outcomes Through Week 24 HealthDay 17:18 Wed, 08 Apr
AAD: Zasocitinib Safe, Effective for Moderate to Severe Plaque Psoriasis in Adults Dermatology Advisor 16:01 Tue, 07 Apr
2026 AAD Annual Meeting: Once Daily Pill to Treat Rare Skin and Muscle Disease Gets Rapid Review by FDA HealthDay 20:21 Mon, 06 Apr
2026 AAD Meeting: Once Daily Pills for Psoriasis and Atopic Dermatitis, New Medications for Vitiligo and Cutaneous Lupus HealthDay 20:21 Mon, 06 Apr
AAD: Zasocitinib Beneficial for Moderate to Severe Plaque Psoriasis in Adults Clinical Pain Advisor 18:52 Mon, 06 Apr
AAD: Ixekizumab + Tirzepatide Boosts Psoriatic Arthritis Outcomes More Than Ixekizumab Monotherapy HealthDay 16:47 Mon, 06 Apr
AAD: Zasocitinib Safe, Effective for Moderate-to-Severe Plaque Psoriasis in Adults HealthDay 18:51 Fri, 03 Apr
Video: Nicotinamide for Skin Cancer Prevention — AAD Expert Insights Dermatology Advisor 16:20 Wed, 01 Apr
Video: Bimekizumab for Hidradentitis Suppurativa — AAD Expert Insights Dermatology Advisor 16:20 Wed, 01 Apr
Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting PR Newswire (Press Release) 14:05 Wed, 01 Apr
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Sanofi (Press Release) 06:12 Tue, 31 Mar
Aad 2026: Targeted oral therapies challenge injected biologics BioWorld 22:05 Mon, 30 Mar Article paywall
Leo Pharma Presents New 12-Month Real-World Data for Tralokinumab at Aad 2026 Business Wire (Press Release) 17:01 Mon, 30 Mar
Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD) AbbVie (Press Release) 13:04 Mon, 30 Mar
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity PR Newswire (Press Release) 19:23 Sat, 28 Mar
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (Aad) Annual Meeting Business Wire (Press Release) 19:01 Sat, 28 Mar
Aad 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis Business Wire (Press Release) 15:02 Sat, 28 Mar
Leo Pharma Announces New Long-Term Data for Spevigo® (spesolimab-sbzo) Injection in Adults with Generalized Pustular Psoriasis at Aad 2026 Business Wire (Press Release) 15:22 Fri, 27 Mar
Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting PR Newswire (Press Release) 14:45 Fri, 27 Mar
AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting PR Newswire (Press Release) 14:00 Fri, 27 Mar
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 Newswise (Press Release) 13:15 Fri, 27 Mar
OLAY Unveils Proprietary Research on Cell Adhesion as a Key Driver of Skin Aging at AAD 2026 PR Newswire (Press Release) 13:09 Fri, 27 Mar
UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa PR Newswire (Press Release) 13:09 Fri, 27 Mar
UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis PR Newswire (Press Release) 13:09 Fri, 27 Mar
